Strategic FDA Submissions & Authoring
Keystone Biologics Advisory provides end-to-end support for FDA regulatory submissions, ensuring technical data is translated into a compelling and compliant narrative. We specialize in authoring and reviewing the Module 3 (CMC) sections for pre-IND meetings, IND applications, and BLA submissions.Pre-IND Engagement
Early, strategic engagement with the FDA is critical to de-risking your development program. We provide expert guidance through the entire pre-IND process:
Strategic Advising: Developing a targeted regulatory strategy and identifying critical questions for the agency.
Document Authoring: Preparing the pre-IND meeting request and comprehensive briefing books.
Agency Interaction: Providing high-level support and attendance during FDA meetings to ensure productive dialogue.
IND and BLA Submissions
We navigate the complexities of Module 3 to build robust, phase-appropriate dossiers that align with the latest 2026 FDA flexible framework.
Regulatory Readiness: Conducting comprehensive gap analyses of your CMC documentation to identify and remediate risks before submission.
Technical Authoring: Full authoring and oversight of manufacturing processes, analytical controls, and risk-mitigation strategies.
Lifecycle Strategy: Proposing regulatory pathways that facilitate a smooth transition from IND-stage development to final BLA licensure.
Our goal is to facilitate timely, strategic engagement with the FDA—positioning your program for successful clinical initiation and accelerated approval.
Strategic FDA Submissions & Authoring
Keystone Biologics Advisory provides end-to-end support for FDA regulatory submissions, ensuring technical data is translated into a compelling and compliant narrative. We specialize in authoring and reviewing the Module 3 (CMC) sections for pre-IND meetings, IND applications, and BLA submissions.Pre-IND Engagement
Early, strategic engagement with the FDA is critical to de-risking your development program. We provide expert guidance through the entire pre-IND process:
Strategic Advising: Developing a targeted regulatory strategy and identifying critical questions for the agency.
Document Authoring: Preparing the pre-IND meeting request and comprehensive briefing books.
Agency Interaction: Providing high-level support and attendance during FDA meetings to ensure productive dialogue.
IND and BLA Submissions
We navigate the complexities of Module 3 to build robust, phase-appropriate dossiers that align with the latest 2026 FDA flexible framework.
Regulatory Readiness: Conducting comprehensive gap analyses of your CMC documentation to identify and remediate risks before submission.
Technical Authoring: Full authoring and oversight of manufacturing processes, analytical controls, and risk-mitigation strategies.
Lifecycle Strategy: Proposing regulatory pathways that facilitate a smooth transition from IND-stage development to final BLA licensure.
Our goal is to facilitate timely, strategic engagement with the FDA—positioning your program for successful clinical initiation and accelerated approval.
